C Lance Cowey News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article TARRYTOWN, N.Y., May 19, 2021 /PRNewswire/   Presentations include first positive clinical data for the fianlimab (LAG-3 inhibitor) and Libtayo combination in advanced melanoma Regeneron will host an investor webcast on Monday, June 7 to provide further updates across its oncology portfolio Regeneron Pharmaceuticals, Inc. (NASDAQ:  REGN) today announced the company will share a range of presentations for its PD-1 inhibitor Libtayo ® (cemiplimab-rwlc) and broader oncology portfolio at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, taking place virtually. Presentations include new clinical data and in-depth analyses on the impact of Libtayo in several advanced cancers, including non-small cell lung cancer (NSCLC), cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC) and melanoma.

United statesEleanor paulAlexanderj stratigosIra winerGeorged yancopoulosC lance coweyRegeneron velocimmuneVesna tosicGuilherme rabinowitsNick freemantleAndreas kuznikOmid hamidDaren kwokRegeneron pharmaceuticalsRegeneron pharmaceuticals incAmerican society of clinical oncology